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Background: Although several studies have evaluated the association between interleukin-1B
(IL1B) polymorphisms and the risk of chronic obstructive pulmonary disease (COPD), most of
these studies have focused on 511C/ T and 31T/ C polymorphisms, and the results of
these studies have been inconsistent. This study was conducted to investigate the association
between four potentially functional polymorphisms of the IL1B gene (3737C/ T,
1464G/ C, 511C/ T, and 31T/ C) and the risk of COPD. In addition, we examined
a potential interaction of the IL1B polymorphisms with the VNTR polymorphism of the IL-1 re-
ceptor antagonist (IL1RN ) gene in determining the risk of COPD.
Methods: The IL1B and IL1RN genotypes were determined in 311 COPD patients and 386
healthy controls.
Results: Individuals with at least one variant allele of the 511C/ T and 31T/ C polymor-
phisms were at a significantly increased risk for COPD when compared to carriers with each
homozygous wild-type allele [adjusted odds ratio (OR) 1.53, 95% confidence interval (CI)
1.03e2.26, PZ 0.03; and adjusted OR 1.50, 95% CI 1.02e2.24, PZ 0.04, respectively]. When
the COPD cases were stratified according to disease severity, the presence of at least oneof Internal Medicine, Kyungpook National University Hospital, Samduk 2a 50, Daegu, 700-412, South
2 53 426 2046.
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1312 J.M. Lee et al.511T and 31C alleles was significantly associated with severe COPD (adjusted OR 2.80, 95%
CI 1.47e5.33, PZ 0.002; and adjusted OR 2.33, 95% CI 1.24e4.40, PZ 0.01, respectively),
however, there was no significant association between the 511C/ T and 31T/ C geno-
types and mild-to-moderate COPD. In addition, individuals carrying at least one IL1RN*2 allele
were at a significantly lower risk for COPD compared to subjects carrying no IL1RN*2 allele
(adjusted OR 0.51, 95% CI 0.26e0.98, PZ 0.04). In haplotype/diplotype analyses, individuals
with one or two copies of the IL1B CCTC haplotype that carried the risk allele at all of the
3737C/ T, 1464G/ C, 511C/ T, and 31T/ C loci, were at a significantly increased
risk of severe COPD when compared with subjects with zero copy of the CCTC haplotype
(adjusted OR 1.96, 95% CI 1.16e3.29, PZ 0.01).
Conclusion: These findings suggest that polymorphisms in the IL1B and IL1RN genes might be
useful markers for determining genetic susceptibility to COPD in a Korean population.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD), which
includes chronic obstructive bronchitis and emphysema, is
defined by a progressive airflow limitation that is not fully
reversible.1,2 Although cigarette smoking is a major known
environmental risk factor for the development of COPD,
only a minority of smokers develop COPD during their life-
time.3 In addition, several studies have demonstrated
familial aggregation of COPD.4,5 Taken together, these find-
ings suggest that genetic factors contribute to the develop-
ment of COPD.1e5
It has long been proposed that chronic inflammation of
the airway and lung parenchyma plays an important role in
the pathogenesis of COPD. Briefly, cigarette smoke and
other inhaled irritants stimulate inflammatory cells such as
macrophages, neutrophils and CD8þ T cells, which then
release a variety of mediators, proteases, and oxidants.
These inflammatory events induce airways remodeling and
parenchymal destruction, which in turn results in airflow
obstruction.6,7 Therefore, genes involved in the regulation
of inflammation are good candidate genes for the genetic
predisposition to COPD.
Interleukin-1 (IL-1), which is a major proinflammatory
cytokine that is primarily produced by monocytes and
macrophages, plays an important role in the pathogenesis
of COPD.8,9 The IL-1 family of cytokines consists of IL-1a,
IL-1b and IL-1 receptor antagonist (IL-1ra), which are
products of the three related genes IL1A, IL1B and
IL1RN.10 IL-1a and IL-1b are agonists of cell membrane
IL-1 type 1 receptor, whereas IL-1ra is a competitive an-
tagonist.11 The genes for these cytokines are clustered
within a 430 kb region on chromosome 2q14.12,13 Polymor-
phisms in the promoter region of the IL1B gene have been
associated with IL-1b production and the risk of various
human diseases including COPD.14e18 The IL1RN gene con-
tains an 86 bp variable number of tandem repeat (VNTR)
polymorphism in intron 2,19 and IL1RN allele 2 (IL1RN*2)
carrying two repeats has been shown to be associated
with increased IL1RN production when compared to the
four-repeat allele, IL1RN*1.20 Consistent with its func-
tional significance, IL1RN*2 has been shown to be associ-
ated with an increased risk of human diseases in which
IL-1 plays an important role in the pathogenesis of the dis-
ease.14e16,21,22Although the association between polymorphisms in the
IL1B and IL1RN genes and the risk of COPD has been inves-
tigated in several studies, the results have been inconsis-
tent between different ethnic populations and within the
same ethnic group.15,23e25 Therefore, to better understand
the role of IL1B and IL1RN polymorphisms on the risk of
COPD, we conducted a caseecontrol study in a Korean pop-
ulation. In this study, we evaluated the association of four
IL1B polymorphisms (3737C/ T, 1464G/ C,
511C/ T and 31T/ C) and their haplotypes with the
risk of COPD because these four polymorphisms were asso-
ciated with IL-1b production in a haplotype-dependent
manner.18 In addition, we evaluated the potential interac-
tion of the IL1B polymorphisms with the IL1RN VNTR poly-
morphism in determining the risk of COPD.Materials and methods
Study population
The patient group consisted of 311 male patients with COPD
who were diagnosed with COPD at the Kyungpook National
University Hospital according to the criteria established by
the NHLBI/WHO Global Initiative for COPD (GOLD).2 The
inclusion criteria for COPD were as follows: chronic respira-
tory symptoms and signs such as cough and dyspnea; post-
bronchodilator FEV1 <80% of the predicted value, FEV1/
FVC <70%, and FEV1 reversibility after inhalation of
200 mg salbutamol <12% of the pre-bronchodilator FEV1.
The severity of COPD was classified by the guidelines of
the GOLD in terms of the percentage predicted FEV1: mild
(>80%), moderate (50e80%), severe (30e50%) or very
severe (<30%). Control subjects (nZ 386) were selected
from a pool of healthy men who visited the general health
check-up center. The enrollment criteria for the controls
were as follows: male, age >45 years, no known disease
and no history of any disease, and no airflow limitation.
All of the cases and the controls were ethnic Koreans who
resided in Daegu City or in the surrounding regions. A
trained interviewer completed detailed questionnaires for
each patient and each control subject. This study was
approved by the institutional review board of the Kyung-
pook National University Hospital, and written informed
consent was obtained from each participant.
Table 1 Characteristics of the study population
Variable COPD (nZ 311) Control (nZ 386) P
Age (years) 65.5  8.1 60.4  8.0 <0.001a
Smoking status <0.001b
Current 171 (55.0)c 205 (53.1)
Former 129 (41.5) 128 (33.2)
Never 11 (3.5) 53 (13.7)
Pack-yearsd 42.6  20.0 30.8  16.9 <0.001a
FEV1
(% predicted)
63.4  26.3 104.9  16.8 <0.001a
FEV1/FVC (%) 49.7  13.1 80.7  7.4 <0.001a
FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity.
a t-test
b c2 test.
c Numbers in parentheses, column percentage.
d In current and former smokers.
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Genotypes of the four IL1B polymorphisms (3737C/ T,
rs4848306; 1464G/ C, rs1143623; 511C/ T, rs16944;
and 31T/ C, rs1143627) were determined by PCR and
melting-curve analysis using fluorescence labeled hybrid-
ization probes (LightCycler, Roche Diagnostic, Mannheim,
Germany). A genotype success rate of greater than 98%
was achieved using the LightCycler. Samples that could
not be scored by the LightCycler were re-genotyped by di-
rect sequencing using an ABI PRISM 3700 genetic analyzer
(Applied Biosystems). The IL1RN VNTR polymorphism (allele
1, four repeats; allele 2, two repeats; allele 3, five repeats;
and allele 4, three repeats) was genotyped using PCR
followed by agarose gel electrophoresis as described previ-
ously.19 To confirm the genotyping results, selected PCR-
amplified DNA samples were examined by DNA sequencing,
and the results were 100% concordant. All genotyping anal-
yses were performed ‘‘blind’’ with respect to the case/con-
trol status in order to ensure quality control. Approximately
10% of the samples were randomly selected to be geno-
typed again by a different investigator, and the results
were 100% concordant.
Statistical analysis
The cases and controls were compared using the Student’s
t-test for continuous variables and a c2 test for categorical
variables. HardyeWeinberg equilibrium for each genotyped
polymorphism was tested using the goodness-of-fit test, as
implemented through SAS Genetics. The LD structure
among polymorphisms was examined with the program
HaploView (http://broad.mit.edu/mpg/haploview). Haplo-
type frequencies were estimated based on a Bayesian algo-
rithm using PHASE 2.1.26 Diplotype (haplotype dosage, an
estimate of the number of copies of the haplotype) for
each individual and for each haplotype with a frequency
>1% was computed by use of that individual’s genotype
data following the method described by Stram et al.27
Unconditional logistic regression analyses were used to cal-
culate the odds ratios (ORs) and 95% confidence intervals
(CIs), with adjustment for possible confounders (age and
pack-years of smoking as continuous variables). In addition
to the overall association analysis, we performed a stratified
analysis according to age, smoking status and severity of
COPD to further explore the association between geno-
types/haplotypes and the risk of COPD in each stratum.
To correct for multiple testing, we applied both the Bonfer-
roni correction based on the effective number of indepen-
dent SNPs (Meff) and a false discovery rate (FDR).
28,29 Meff
was 1.88, giving a Bonferroni-corrected threshold for asso-
ciation of PZ 0.0266. To assess the potential interaction
between genotype/haplotype and smoking (smoking status
or pack-years of smoking), we first included the interaction
term in the logistic model. The interaction between geno-
type/haplotype and smoking was not statistically signifi-
cant, and this was removed from the model. The
homogeneity test was done to compare the difference
between genotype/diplotype-related ORs of different
groups. All of the analyses were performed using Statistical
Analysis Software for Windows, version 9.1.3 (SAS institute,
Gary, NC, USA).Results
The baseline characteristics of the cases and controls
enrolled in this study are shown in Table 1. FEV1 and the
FEV1/FVC ratio were significantly lower in the COPD group
than in the control group.
The genotype and polymorphic allele frequencies of the
IL1B and IL1RN polymorphisms in the cases and controls are
shown in Tables 2 and 3, respectively. The genotype distri-
butions of the four IL1B polymorphisms in the controls were
consistent with the HardyeWeinberg equilibrium. The dis-
tribution of the IL1B 511C/ T and 31T/ C genotypes
among the cases were significantly different from those
among the controls (PZ 0.01, respectively). Individuals
with at least one variant allele of the 511C/ T and
31T/ C polymorphisms were at a significantly increased
risk for COPD when compared to carriers with each homozy-
gous wild-type allele [adjusted OR 1.53, 95% CI 1.03e2.26,
PZ 0.03, corrected P (Pc) for multiple testing by
MeffZ 0.06; and adjusted OR 1.50, 95% CI 1.02e2.24,
PZ 0.04, PcZ 0.08, respectively]. When the cases were
stratified according to disease severity, the presence of at
least one 511T and 31C allele was significantly associ-
ated with severe COPD [adjusted OR 2.80, 95% CI
1.47e5.33, PZ 0.002, PcZ 0.003; and adjusted OR 2.33,
95% CI 1.24e4.40, PZ 0.01, PcZ 0.02, respectively), how-
ever, there was no significant association between the
511C/ T and 31T/ C genotypes and mild-to-
moderate COPD (PZ 0.002 and PZ 0.02, respectively,
test for homogeneity). For the IL1B 3737C/ T and
1464G/ C polymorphisms, there was no significant dif-
ference in the distribution of genotypes observed between
the overall cases and controls. However, when the cases
were stratified according to disease severity, the presence
of at least one 3737T and 1464C allele was associated
with an increased risk of severe COPD, with a borderline
statistical significance, when compared to each homozy-
gous wild-type genotype (adjusted OR 2.00, 95% CI
1.01e3.93, PZ 0.05, PcZ 0.09; and adjusted OR 1.68,
95% CI 1.00e2.83, PZ 0.05, PcZ 0.09, respectively).
For the IL1RN VNTR polymorphism, the frequency of
the IL1RN*2 allele was significantly lower in the cases
Table 2 Genotype frequencies of IL-1B polymorphisms among controls and cases and their association with the risk of CO
Severity of COPD
Controls (nZ 386) All cases (nZ 311) GOLD I þ II (nZ 198) GOLD III þ IV (nZ 113)
No. (%) No. (%) Pa OR (95% CI)b Pb No. (%) Pa OR (95% CI)b Pb No. (%) Pa OR (95% CI)b Pb
IL-1B
3737C/ T
CC 117 (30.3) 92 (29.6) 0.26 1.36 (0.83e2.24) 0.22 55 (27.8) 0.54 1.16 (0.67e2.02) 0.59 37 (32.7) 0.15 2.13 (1.00e4.50)d 0.05
CT 190 (49.2) 169 (54.3) 1.34 (0.85e2.12) 0.20 107 (54.0) 1.19 (0.72e1.96) 0.50 62 (54.9) 1.92 (0.95e3.89) 0.07
TT 79 (20.5) 50 (16.1) 1.00 36 (18.2) 1.00 14 (12.4) 1.00
C-carrier 307 (79.5) 261 (83.9) 1.35 (0.88e2.09) 0.17 162 (81.8) 1.18 (0.73e1.90) 0.50 99 (87.6) 2.00 (1.01e3.93) 0.05
C allele 0.549 0.568 0.49 0.548 0.97 0.602 0.16
1464G/ C
GG 133 (34.5) 91 (29.3) 0.25 1.00 62 (31.3) 0.47 1.00 29 (25.7) 0.20 1.00
GC 184 (47.7) 167 (53.7) 1.33 (0.92e1.94) 0.13 105 (53.0) 1.26 (0.83e1.91) 0.28 62 (54.9) 1.65 (0.95e2.84) 0.07
CC 69 (17.9) 53 (17.1) 1.23 (0.75e2.00) 0.41 31 (15.7) 1.05 (0.60e1.84) 0.87 22 (19.5) 1.77 (0.89e3.54) 0.10
C-carrier 253 (65.5) 220 (70.7) 1.30 (0.91e1.86) 0.14 136 (68.7) 1.20 (0.81e1.79) 0.36 84 (74.3) 1.68 (1.00e2.83) 0.05
C allele 0.417 0.439 0.41 0.422 0.88 0.469 0.16
511C/ T
CC 107 (27.7) 62 (19.9) 0.01c 1.00 47 (23.7) 0.14 1.00 15 (13.3) 0.004c 1.00
CT 175 (45.3) 174 (56.0) 1.67 (1.10e2.53) 0.02c 107 (54.0) 1.35 (0.86e2.13) 0.20 67 (59.3) 2.99 (1.53e5.83)e 0.001c
TT 104 (26.9) 75 (24.1) 1.29 (0.80e2.06) 0.30 44 (22.2) 1.00 (0.59e1.70) 1.00 31 (27.4) 2.47 (1.18e5.16)f 0.02c
T-carrier 279 (72.3) 249 (80.1) 1.53 (1.03e2.26) 0.03 151 (76.3) 1.22 (0.80e1.88) 0.36 98 (86.7) 2.80 (1.47e5.33)g 0.002c
T allele 0.496 0.521 0.36 0.492 0.90 0.571 0.05
31T/ C
TT 100 (25.9) 58 (18.7) 0.01c 1.00 43 (21.7) 0.06 1.00 15 (13.3) 0.01c 1.00
TC 177 (45.9) 179 (57.6) 1.67 (1.09e2.55) 0.02c 111 (56.1) 1.38 (0.87e2.20) 0.17 68 (60.2) 2.57 (1.33e4.98)h 0.005c
CC 109 (28.2) 74 (23.8) 1.21 (0.75e1.95) 0.45 44 (22.2) 0.96 (0.56e1.64) 0.87 30 (26.6) 1.92 (0.92e4.00)h 0.08
C-carrier 286 (74.1) 253 (81.4) 1.50 (1.00e2.24) 0.05 155 (78.3) 1.23 (0.79e1.90) 0.37 98 (86.7) 2.33 (1.24e4.40)i 0.01c
C allele 0.512 0.526 0.60 0.503 0.77 0.566 0.15
a c2 test for either genotype distributions or allele frequencies between the controls and cases.
b ORs (95% CIs) and corresponding P-values were calculated by logistic regression, adjusted for age and pack-years of smoking.
c P-value is statistically significant, based on Bonferroni correction for the effective number of independent tests (MeffZ 1.88, d
threshold P-valueZ 0.0266).
d Test for homogeneity between genotype-related ORs of mild-to-moderate COPD and severe COPD: PZ 0.04.
e Test for homogeneity between genotype-related ORs of mild-to-moderate COPD and severe COPD: PZ 0.004.
f Test for homogeneity between genotype-related ORs of mild-to-moderate COPD and severe COPD: PZ 0.005.
g Test for homogeneity between genotype-related ORs of mild-to-moderate COPD and severe COPD: PZ 0.002.
h Test for homogeneity between genotype-related ORs of mild-to-moderate COPD and severe COPD: PZ 0.03.
i Test for homogeneity between genotype-related ORs of mild-to-moderate COPD and severe COPD: PZ 0.02.
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Polymorphisms in the IL1B and IL1RN genes in COPD 1315than in the controls (2.4% vs 5.6%, PZ 0.003). Individ-
uals carrying at least one IL1RN*2 allele were at a signif-
icantly lower risk for COPD compared to subjects
carrying no IL1RN*2 allele (adjusted OR 0.51, 95% CI
0.26e0.98, PZ 0.04; Table 3). The IL1RN VNTR poly-
morphism was not linked to any of the four IL1B poly-
morphisms in LD analysis.
The four IL1B polymorphisms were in LD (jD0j value, range
from 0.90 to 0.95), and we observed 14 haplotypes out of the
possible 16 (24) haplotypes. Among these haplotypes, ten
had a frequency of less than 1% and were therefore pooled
into a single group. The remaining four haplotypes ac-
counted for 96.9% of the chromosomes obtained from the
697 subjects (controls 96.6% and cases 97.3%). Table 4 shows
the inferred haplotype distributions of the controls and
cases, as well as the risk of COPD according to haplotype.
Consistent with the results of the genotyping analyses, the
CCTC haplotype, which carried the risk allele at all of the
3737C/ T, 1464G/ C, 511C/ T, and 31T/ C
loci, was associated with an increased risk of severe COPD,
although it was only marginally significant (adjusted OR
1.39, 95% CI 1.00e1.93, PZ 0.05).
We next examined the associations between the diplo-
types of the four IL1B haplotypes (CGCT, CGTC, CCTC, and
TGCT) and the risk of COPD. There was no significant asso-
ciation between the IL1B diplotypes and the risk of COPD as
a whole. However, when the cases were stratified according
to disease severity, the diplotypes carrying one or two cop-
ies of the CCTC haplotype were associated with a signifi-
cantly increased risk of severe COPD when compared with
the diplotypes carrying zero copies of the CCTC haplotype
(a dominant model for the CCTC haplotype, adjusted OR
1.96, 95% CI 1.16e3.29, PZ 0.01, Table 4), whereas there
was no significant association between the IL1B diplotypes
and mild-to-moderate COPD (PZ 0.04, test for
homogeneity).
Table 5 shows the combined effect of the IL1B CCTC
haplotypes/diplotypes and IL1RN VNTR polymorphism on
the risk of COPD. Because the presence of at least one
copy of the IL1B CCTC haplotype [‘‘CCTC haplotype
(þ)’’] was associated with an increased risk for COPD and
the presence of at least one IL1RN*2 allele [‘‘IL1RN*2 allele
(þ)’’] was protective against COPD, the subjects were
categorized into 4 groups according to the presence of
the CCTC haplotype and the IL1RN*2 allele [group I,
CCTC haplotype (þ)/IL1RN*2 allele (); group II, CCTC
haplotype (þ)/IL1RN*2 allele (þ); group III, CCTC haplo-
type ()/IL1RN*2 allele (); and group IV, CCTC haplotype
()/IL1RN*2 allele (þ)]. The frequency distribution of the
combined genotypes in the COPD cases significantly dif-
fered from that of the controls (PZ 0.02). Compared to
group 1, which had the CCTC haplotype (þ) and the
IL1RN*2 allele (), the combined group (groups 2e4) with
the CCTC haplotype () and/or the IL1RN*2 allele (þ)
was at a significantly decreased risk of COPD (adjusted
OR 0.64, 95% CI 0.45e0.89, PZ 0.01). When the cases
were stratified based on disease severity, the protective
effect of the CCTC haplotype () and the IL1RN*2 allele
(þ) was more pronounced for severe COPD patients than
for mild-to-moderate COPD patients (adjusted OR 0.48,
95% CI 0.29e0.79, PZ 0.004 vs adjusted OR 0.68, 95% CI
0.46e0.99, PZ 0.05).
Table 4 Distribution of inferred IL-1B haplotypes in controls and cases and their association with the risk of COPD
Severity of COPD
Controls (nZ 772) All cases (nZ 622) GOLD I þ II (nZ 396) GOLD III þ IV (nZ 226)
Haplotypes No. (%) No. (%) Pa OR (95% CI)b Pb No. (%) Pa OR (95% CI)b Pb No. (%) Pa OR (95% CI)b Pb
Ht1, CGCT 37 (4.8) 26 (4.2) 0.85 0.99 (0.56e1.75) 0.98 18 (4.5) 0.96 1.13 (0.60e2.12) 0.71 8 (3.5) 0.21 0.79 (0.34e1.85) 0.59
Ht2, CGTC 68 (8.8) 58 (9.3) 1.04 (0.70e1.56) 0.85 34 (8.6) 0.95 (0.60e1.51) 0.83 24 (10.6) 1.16 (0.68e1.99) 0.58
Ht3, CCTC 308 (39.9) 260 (41.8) 1.12 (0.89e1.42) 0.35 157 (39.6) 1.03 (0.79e1.34) 0.84 103 (45.6) 1.39 (1.00e1.93) 0.05
Ht4, TGCT 333 (43.1) 261 (42.0) 0.93 (0.73e1.17) 0.51 173 (43.7) 0.99 (0.76e1.29) 0.95 88 (38.9) 0.82 (0.59e1.14) 0.23
Others 26 (3.4) 17 (2.7) - 14 (3.5) - 3 (1.3) -
Controls
(nZ 386)
All cases
(nZ 311)
GOLD I þ II
(nZ 198)
GOLD III þ IV
(nZ 113)
Copy no. of Ht3, CCTC No. (%) No. (%) Pa OR (95% CI)b Pb No. (%) Pa OR (95% CI)b Pb No. (%) Pa OR (95% CI)b Pb
0 143 (37.0) 98 (31.5) 0.16 1.00 68 (34.3) 0.32 1.00 30 (26.5) 0.11 1.00
1 177 (45.9) 165 (53.1) 1.40 (0.97e2.02) 0.07 103 (52.0) 1.31 (0.87e1.97) 0.20 62 (54.9) 1.92 (1.13e3.32) 0.01c
2 66 (17.1) 48 (15.4) 1.21 (0.74e1.99) 0.44 27 (13.6) 0.99 (0.56e1.75) 0.96 21 (18.6) 2.06 (1.02e4.14)e 0.04d
0 143 (37.0) 98 (31.5) 0.13 1.00 68 (34.3) 0.52 1.00 30 (26.5) 0.04 1.00
1 or 2 243 (63.0) 213 (68.5) 1.35 (0.95e1.92) 0.09 130 (65.7) 1.23 (0.83e1.81) 0.31 83 (73.5) 1.96 (1.16e3.29)f 0.01c
a Global P-value.
b ORs (95% CIs) and corresponding P-values were calculated by logistic regression, adjusted for age and pack-years of smoking.
c False discovery rateZ 0.045.
d False discovery rateZ 0.12.
e Test for homogeneity between diplotype-related ORs between mild-to-moderate COPD and severe COPD: PZ 0.02.
f Test for homogeneity between diplotype-related ORs between mild-to-moderate COPD and severe COPD: PZ 0.04.
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Although several studies have been conducted to evaluate
the association between IL1B polymorphisms and the risk of
COPD, most of these studies have focused on the IL1B
511C/ T and 31T/ C polymorphisms, and the results
have been inconsistent. Therefore, this study investigated
the association between four potentially functional poly-
morphisms of the IL1B gene (3737C/ T, 1464G/ C,
511C/ T, and 31T/ C) and the risk of COPD. In addi-
tion, we examined a potential interaction of the IL1B poly-
morphisms with the IL1RN VNTR polymorphism for
determining the risk of COPD. The results of this study pro-
vide the first evidence that the IL1B 3737C/ T and
1464G/ C polymorphisms, as well as the 511C/ T
and 31T/ C polymorphisms, contribute to the risk of
COPD depending on the context of the haplotype. In addi-
tion, we found that the IL1RN*2 allele of the IL1RN VNTR
polymorphism also influenced the risk of COPD.
Several polymorphisms in the IL1B gene have been
reported to be associated with IL-1b production. El-Omar
et al.14 reported that the T allele of the 31T/ C poly-
morphism, located in a TATA box of the IL1B promoter,
was associated with higher nuclear protein binding than
the 31C allele in lipopolysaccharide-activated monocytes,
whereas the 511C/ T polymorphism did not have an
effect on the nuclear protein binding. In addition, Lind
et al.30 also reported that the31T allele had a significantly
higher promoter activity than the 31C allele in A549 lung
cancer cells. Even though these two groups found a consis-
tent finding of an association between the 31T/ C poly-
morphism and IL-1b production, neither group examined
the effects of the IL1B haplotypes of the 511C/ T and
31T/ C polymorphisms on IL-1b production. Chakravorty
et al.31 investigated the effects of haplotypes composed of
the 511C/ T and 31T/ C polymorphisms on the IL1B
promoter activity in HeLa and U937 cells. In this study,
the promoter activity of the 511C/31T haplotype was
significantly higher than that of the 511T/31C haplo-
type, whereas the promoter activity of the 511T/31T
haplotype was significantly lower than that of the 511T/
31C haplotype, even though it carries the 31T allele.
These results suggest that the promoter activity of IL1B is
determined by the allelic interaction between the
511C/ T and 31T/ C polymorphisms. Recently,
Chen et al.18 searched for functional polymorphisms in
the IL1B gene and found that the 3737C/ T and
1464G/ C polymorphisms, as well as the 511C/ T
and 31T/ C polymorphisms, affect IL-1b production. In
addition, they found that an individual polymorphism had
either an up- or down-regulatory effect on promoter activ-
ity depending on haplotype context, and that the promoter
activity of IL1B was determined by haplotypes incorporat-
ing these four promoter polymorphisms (3737C/ T,
1464G/ C, 511C/ T, and 31T/ C). In their study,
four haplotypes (ht1, CGCT; ht2, CGTC; ht3, CCTC; and
ht4, TCTC) were found to account for >98% of the esti-
mated haplotypes observed in Caucasians and African-
Americans, and among the four common haplotypes, ht1
had significantly lower activity than the other three haplo-
types (hts 2e4), whereas ht2 had higher activity than the
Figure 1 Linkage disequilibrium values jD0j (100) between
polymorphisms in the IL1B and IL1RN genes.
1318 J.M. Lee et al.ht1, ht3, and ht4. This haplotype-dependent effect of the
four IL1B polymorphisms on gene expression suggests that
single polymorphism analysis may not be sufficient for char-
acterization of the IL1B genotype/phenotype or genotype/
disease relationships. Therefore, our investigation was
extended to an analysis of the IL1B haplotypes composed
of the four polymorphisms. In the haplotype analysis, only
the CCTC haplotype containing susceptible alleles at all
of the four polymorphism loci was associated with an
increased risk of COPD. This result suggests that the four
polymorphisms of the IL1B gene contribute to the risk of
COPD depending on the context of the haplotype, and
also suggests that haplotype analysis may be a more suit-
able tool for assessing the disease association than analysis
of individual polymorphisms.
The distribution of IL1B haplotypes composed of the
3737C/ T, 1464G/ C, 511C/ T, and 31T/ C
polymorphisms has been reported to be remarkably differ-
ent between Caucasians and African-Americans.18 In the
present study, the frequencies of the four common IL1B
haplotypes (ht1, ht2, ht3, and ht4) among healthy Koreans
were 4.8%, 8.8%, 39.9% and 43.1%, respectively, which is
significantly different from the frequencies observed in
Caucasians (20.0%, 6.0%, 27.7%, and 44.8%, respectively)
and African-Americans (14.7%, 46.1%, 10.6%, and 27.3%,
respectively). In addition, the distribution of the IL1RN
VNTR genotypes among healthy Koreans was significantly
different from those of Caucasians and Egyptians, and the
frequency (0.056) of the IL1RN*2 allele among healthy
Koreans was significantly lower than those of Caucasians
and Egyptians (0.287 and 0.201, respectively).22,24 More-
over, in contrast to Japanese and Egyptians,24 the IL1RN
VNTR polymorphism was not strongly linked with any of
the four IL1B polymorphisms in Koreans. Inter-ethnic differ-
ences of the distributions of the IL1B and IL1RN genotype
and haplotype suggest that the effect of IL1B and IL1RN
polymorphisms on the risk of disease may be different in
different ethnic populations.
Several studies have investigated the relationship
between IL1B and IL1RN polymorphisms and the risk of
COPD,15,23e25 however, the results of these studies have
been inconsistent. Joos et al.15 investigated the association
of the IL1B 511C/ T and IL1RN VNTR polymorphisms with
the rate of decline of lung function in smokers from a Cana-
dian population. In their study, although neither of the
polymorphisms evaluated in their study were correlated
with the rate of decline of lung function, the 511T/
IL1RN*1 haplotype was associated with a rapid decline of
lung function, whereas the 511T/IL1RN*2 haplotype was
protective against the rapid decline of lung function. In
contrast to this Canadian study, Hegab et al.24 reported
that the 511 TT genotype and the 31 CC genotype
were protective against COPD (c2Z 4.74, PZ 0.03,
respectively), but that the IL1RN VNTR polymorphism was
not associated with the risk of COPD in an Egyptian popula-
tion. The results of studies performed in Asian populations
have also been inconsistent.23e25 Ishii et al.23 reported that
neither IL1B 511C/ T nor IL1RN VNTR polymorphisms
were significantly associated with susceptibility to COPD
in a Japanese population. In addition, Hegab et al.24
reported that the IL1B 511C/ T, 31T/ C and
þ3954C/ T, and IL1RN polymorphisms were notassociated with the risk of COPD in a Japanese population.
However, Asada et al.25 reported that Japanese carrying
the 511 TT genotype had a significantly lower risk of
COPD than Japanese with the 511 CC or CT genotype,
but that the IL1B 31C/ T polymorphism was not associ-
ated with the risk of COPD. Although the reasons for the dif-
ferent results across studies are unclear, the discrepancies
may be due to different ethnicities of the study popula-
tions. The allele and genotype frequencies of the IL1B
and IL1RN polymorphisms, as well as the status of LD
between the polymorphisms, vary greatly between ethnic
groups.22,24,32,33 Therefore, the genetic effects of the
IL1B and IL1RN polymorphisms on the susceptibility to
COPD may be different in different ethnic populations. In
addition, in the present study, the IL1B genotype/haplo-
type was associated with the risk of severe COPD but not
with the risk of mild-to-moderate COPD, suggesting that
the discrepancies may arise from differences in the severity
of the COPD cases across different studies. Furthermore,
the discrepancies may be related to differences in the dis-
tribution of COPD phenotypes across different studies.
COPD is a heterogeneous disorder that includes chronic
obstructive bronchitis, emphysema and small airway dis-
ease. Although combination of these disorders under a sin-
gle diagnosis may be useful for clinical identification and
management of COPD patients, it may complicate the
genetic analysis of COPD. The phenotypes of emphysema,
chronic bronchitis, and small airway disease share some
similar pathophysiology, and likely share some similar
genetic determinants; however, there may also be diver-
gent underlying pathways involved in their develop-
ment.34,35 Therefore, it is possible that the effects of the
IL1B and IL1RN polymorphisms on the risk of COPD will dif-
fer according to the phenotype of COPD. The inadequacies
in the study design, such as non-random sampling, limited
sample sizes and the pitfalls arising from unknown con-
founders, also need to be considered.
In a number of genome-wide linkage analyses, (Fig. 1)
chromosome 2q has been found to contain genes that
Polymorphisms in the IL1B and IL1RN genes in COPD 1319contribute to the susceptibility to COPD.36,37 For example;
DeMeo et al.38 reported that SERPINE2, one of the genes lo-
cated at 2q, was linked to COPD susceptibility. In addition,
the IL1B and IL1RN genes are located on chromosome
2q14.2, and this region harbors several candidate genes
for COPD, including IL1A and IL1F family genes. Further-
more, this region shows strong linkage in genome-wide
screens. Therefore, the potential relationship of these can-
didate genes with COPD needs to be evaluated in future
studies.
In conclusion, we found that the IL1B 3737C/ T and
1464G/ C polymorphisms, as well as the 511C/ T
and 31T/ C polymorphisms, contribute to the risk of
COPD depending on the context of the haplotype. In addi-
tion, we found that the effect of the IL1B polymorphisms
on the risk of COPD was more pronounced in patients
with severe COPD. Furthermore, we found that the
IL1RN*2 allele of the IL1RN VNTR polymorphism also influ-
enced the risk of COPD. Taken together, these findings sug-
gest that polymorphisms in the IL1B and IL1RN genes might
be useful markers for determining genetic susceptibility to
COPD. However, because the IL1B and IL1RN polymorphisms
vary between different ethnic groups, further studies are
needed to clarify the association of the IL1B and IL1RN
polymorphisms with the risk of COPD in diverse ethnic
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